Fate Therapeutics (NASDAQ:FATE) Lowered to “Sell” Rating by StockNews.com
StockNews.com cut shares of Fate Therapeutics (NASDAQ:FATE – Free Report) from a hold rating to a sell rating in a research note issued to investors on Tuesday. FATE has been the topic of a number of other reports. Stifel Nicolaus cut their target price on Fate Therapeutics from $5.00 to $3.00 and set a “hold” […]
StockNews.com cut shares of Fate Therapeutics (NASDAQ:FATE – Free Report) from a hold rating to a sell rating in a research note issued to investors on Tuesday. FATE has been the topic of a number of other reports. Stifel Nicolaus cut their target price on Fate Therapeutics from $5.00 to $3.00 and set a “hold” […]
